{
    "clinical_study": {
        "@rank": "70414", 
        "arm_group": [
            {
                "arm_group_label": "DAG oil", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "TAG oil", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Diacylglycerol oil has been shown to lower postprandial and fasting serum triacylglycerol\n      levels and reduce body fat. The investigators hypothesize that replacing dietary fat with\n      diacylglycerol oil reduces excess body fat in type 2 diabetic patients and that\n      diacylglycerol oil has a beneficial effect on cardiovascular risk factors in Chinese type 2\n      diabetic patients."
        }, 
        "brief_title": "Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism", 
        "condition": [
            "Insulin Sensitivity", 
            "Type 2 Diabetes", 
            "Cardiovascular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Insulin Resistance"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Type 2 diabetic patients, blood sugar levels were stabilized between 7.0\uff0d10.0 mmol/L\n\n          2. Male, aged 40 - 70 years old, Female, aged post-menopausal - 70 years old.\n\n          3. Overweight/obese patients (BMI 25 - 40 kg/m2)\n\n          4. Currently under diet therapy for diabetes mellitus\n\n          5. Understands the procedures and willing to participate in the study\n\n        Exclusion Criteria:\n\n          1. Patients who unwilling to give informed consent\n\n          2. Type 1 diabetic patients\n\n          3. Familial hyperlipemia patients or blood triacylglycerol concentration > 400 mg/dl\n\n          4. Patients with a history of cardiovascular disease and/or arteriosclerotic disease\n\n          5. Patients with a history of cerebrovascular disease\n\n          6. Patients with serious hepatic disease and/or renal disease\n\n          7. Patients with malignancy\n\n          8. Participation in another clinical study within 30 days prior to screening period.\n\n          9. Has a condition the doctor in charge believes would interfere with evaluation of the\n             subject, or may put subject at undue risk"
            }, 
            "gender": "Both", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "127", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802541", 
            "org_study_id": "P031217"
        }, 
        "intervention": [
            {
                "arm_group_label": "DAG oil", 
                "intervention_name": "diacylglycerol oil", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "TAG oil", 
                "intervention_name": "triacylglycerol oil", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "diacylglycerol oil", 
            "insulin sensitivity", 
            "type 2 diabetes", 
            "cardiovascular disease", 
            "risk factors"
        ], 
        "lastchanged_date": "February 28, 2013", 
        "official_title": "Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism", 
        "overall_official": {
            "last_name": "Duo Li, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "insulin resistance", 
            "time_frame": "120 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802541"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Duo li", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}